



Universiteit  
Leiden  
The Netherlands

## Statistical modelling of time-varying covariates for survival data

Spreafico, M.

### Citation

Spreafico, M. (2022, October 12). *Statistical modelling of time-varying covariates for survival data*. Retrieved from <https://hdl.handle.net/1887/3479768>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3479768>

**Note:** To cite this publication please use the final published version (if applicable).

# Bibliography

- [1] O. Aalen. Nonparametric inference for a family of counting processes. *Annals of Statistics*, 6(4):701–726, 1978.
- [2] O. O. Aalen, R. J. Cook, and K. Røysland. Does Cox analysis of a randomized survival study yield a causal treatment effect? *Lifetime data analysis*, 21(4):579–593, 2015.
- [3] AIFA – Agenzia Italiana del Farmaco. *Accesso al farmaco, Autorizzazione dei farmaci*. <https://www.aifa.gov.it/autorizzazione-dei-farmaci>
- [4] AIFA – Agenzia Italiana del Farmaco. *Banca Dati Farmaci, Ricerca per Principio Attivo*. <https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/cerca-per-principio-attivo> (2018-09-08).
- [5] AIFA – Agenzia Italiana del Farmaco. *Linee guida per la classificazione e conduzione degli studi osservazionali sui farmaci*. [http://www.agenziafarmaco.gov.it/sites/default/files/det\\_20marzo2008.pdf](http://www.agenziafarmaco.gov.it/sites/default/files/det_20marzo2008.pdf)
- [6] J. Aitchison. *The Statistical Analysis of Compositional Data*. Chapman & Hall Ltd, 1986.
- [7] H. Akaike. Information Theory and an Extension of the Maximum Likelihood Principle. In B. N. Petrov and F. Csaki, editors, *Proceedings of the 2nd International Symposium on Information Theory*, pages 267–281. Budapest: Akademiai Kiado, 1973.
- [8] H. S. Al-malky, S. E. A. Harthi, and A.-M. M. Osman. Major obstacles to doxorubicin therapy: Cardiotoxicity and drug resistance. *Journal of Oncology Pharmacy Practice*, 26(2):434–444, 2020.
- [9] S. A. Aldossary. Review on pharmacology of cisplatin: Clinical use, toxicity and mechanism of resistance of cisplatin. *Biomedical and Pharmacology Journal*, 12(1):07–15, 2019.
- [10] V. Allan, S. V. Ramagopalan, J. Mardekian, *et al.* Propensity score matching and inverse probability of treatment weighting to address confounding by indication in comparative effectiveness research of oral anticoagulants. *Journal of comparative effectiveness research*, 9(9):603–614, 2020.
- [11] L. D. A. F. Amorim and J. Cai. Modelling recurrent events: a tutorial for analysis in epidemiology. *International Journal of Epidemiology*, 44(1):324–333, 2014.
- [12] P. K. Andersen and R. D. Gill. Cox’s regression model for counting processes: A large sample study. *The Annals of Statistics*, 10(4):1100–1120, 1982.
- [13] P. K. Andersen and N. Keiding. Multi-state models for event history analysis. *Statistical Methods in Medical Research*, 11(2):91–115, 2002.
- [14] S. E. Andrade, K. H. Kahler, F. Frech, and K. A. Chan. Methods for evaluation of medication adherence and persistence using automated databases. *Pharmacoepidemiology & Drug Safety*, 15(8):565–574, 2006.
- [15] J. K. Anninga, H. Gelderblom, M. Fiocco, *et al.* Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand? *European Journal of Cancer*, 47(16):2431–2445, 2011.

## Bibliography

- [16] M. W. Arisido, L. Antolini, D. Bernasconi, *et al.* Joint model robustness compared with the time-varying covariate Cox model to evaluate the association between a longitudinal marker and a time-to-event endpoint. *BMC Med Res Methodol*, 19:222, 2019.
- [17] I. Arnet, M. Greenland, M. W. Knuiman, *et al.* Operationalization and validation of a novel method to calculate adherence to polypharmacy with refill data from the australian pharmaceutical benefits scheme (PBS) database. *Clinical Epidemiology*, 10:1181–1194, 2018.
- [18] P. C. Austin, A. Latouche, and J. P. Fine. A review of the use of time-varying covariates in the Fine-Gray subdistribution hazard competing risk regression model. *Statistics in Medicine*, 39(2):103–113, 2020.
- [19] P. C. Austin and E. A. Stuart. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. *Statistics in Medicine*, 34(28):3661–3679, 2015.
- [20] S. Bacci, S. Pandolfi, and F. Pennoni. A Comparison of Some Criteria for States Selection in the Latent Markov Model for Longitudinal Data. *Advances in Data Analysis and Classification*, 8(2):125–145, 2014.
- [21] S. Baraldo, F. Ieva, A. M. Paganoni, and V. Vitelli. Outcome prediction for heart failure telemonitoring via generalized linear models with functional covariates. *Scandinavian Journal of Statistics*, 40(3):403–416, 2013.
- [22] F. Bartolucci, A. Farcomeni, and F. Pennoni. *Latent Markov Models for Longitudinal Data*. Chapman & Hall/CRC, Boca Raton, 2013.
- [23] F. Bartolucci, A. Farcomeni, and F. Pennoni. Latent Markov models: a review of a general framework for the analysis of longitudinal data with covariates. *TEST*, 23:433–465, 2014.
- [24] F. Bartolucci, M. Lupporelli, and G. E. Montanari. Latent Markov model for longitudinal binary data: An application to the performance evaluation of nursing homes. *The Annals of Applied Statistics*, 3(2):611 – 636, 2009.
- [25] F. Bartolucci, G. E. Montanari, and S. Pandolfi. Three-step estimation of latent Markov models with covariates. *Computational Statistics & Data Analysis*, 83:287–301, 2015.
- [26] F. Bartolucci, S. Pandolfi, and F. Pennoni. LMest: An R Package for Latent Markov Models for Longitudinal Categorical Data. *Journal of Statistical Software*, 81(4):1–38, 2017.
- [27] P. C. Baumgartner, R. B. Haynes, K. E. Hersberger, and I. Arnet. A systematic review of medication adherence thresholds dependent of clinical outcomes. *Frontiers in pharmacology*, 9:1290, 2018.
- [28] B. N. Bekele and P. F. Thall. Dose-Finding Based on Multiple Toxicities in a Soft Tissue Sarcoma Trial. *Journal of the American Statistical Association*, 99(465):26–35, 2004.
- [29] M. J. Bijlsma, F. Janssen, and E. Hak. Estimating time-varying drug adherence using electronic records: extending the proportion of days covered (PDC) method. *Pharmacoepidemiology & Drug Safety*, 25(3):325–332, 2016.
- [30] D. A. Binder. Fitting cox’s proportional hazards models to survey data. *Biometrika*, 79:139–147, 1992.
- [31] M. W. Bishop, Y. C. Chang, M. D. Krailo, *et al.* Assessing the Prognostic Significance of Histologic Response in Osteosarcoma: A Comparison of Outcomes on CCG-782 and INT0133-A Report From the Children’s Oncology Group Bone Tumor Committee. *Pediatric blood & cancer*, 63(10):1737–1743, 2016.
- [32] N. E. Breslow. Analysis of survival data under the proportional hazards model. *International Statistical Review/Revue Internationale de Statistique*, pages 45–57, 1975.

- [33] E. R. Brown, J. G. Ibrahim, and V. DeGruttola. A flexible b-spline model for multiple longitudinal biomarkers and survival. *Biometrics*, 61(1):64–73, Mar. 2005.
- [34] J. Cai and D. E. SchaubeL. Marginal Means/Rates Models for Multiple Type Recurrent Event Data. *Lifetime Data Analysis*, 10:121–138, 2004.
- [35] M. Carhini, M. Suárez-Fariñas, and R. G. Maki. A Method to Summarize Toxicity in Cancer Randomized Clinical Trials. *Clinical Cancer Research*, 24(20):4968–4975, 2018.
- [36] A. Charles-Nelson, S. Katsahian, and C. Schramm. How to analyze and interpret recurrent events data in the presence of a terminal event: An application on readmission after colorectal cancer surgery. *Statistics in Medicine*, 38(18):3476–3502, 2019.
- [37] X. Chen, Q. Wang, J. Cai, and V. Shankar. Semiparametric additive marginal regression models for multiple type recurrent events. *Lifetime data analysis*, 18(4):504–527, 2012.
- [38] Y. Chi and J. G. Ibrahim. Joint Models for Multivariate Longitudinal and Multivariate Survival Data. *Biometrics*, 62(2):432–445, 2006.
- [39] P. J. Clare, T. A. Dobbins, and R. P. Mattick. Causal models adjusting for time-varying confounding—a systematic review of the literature. *International journal of epidemiology*, 48(1):254–265, 2019.
- [40] S. R. Cole and C. E. Frangakis. The Consistency Statement in Causal Inference. *Epidemiology*, 20(3-5), 2009.
- [41] S. R. Cole and M. A. Hernán. Constructing Inverse Probability Weights for Marginal Structural Models. *American Journal of Epidemiology*, 168(6):656–664, 2008.
- [42] L. M. Collins and S. Lanza. *Latent Class and Latent Transition Analysis: With Applications in the Social, Behavioral, and Health Sciences*. John Wiley and Sons Inc, 2010.
- [43] M. Collins, M. Wilhelm, R. Conyers, *et al.* Benefits and Adverse Events in Younger Versus Older Patients Receiving Neoadjuvant Chemotherapy for Osteosarcoma: Findings From a Meta-Analysis. *Journal of Clinical Oncology*, 31(18):2303–2312, 2013.
- [44] R. J. Cook and J. F. Lawless. *The Statistical Analysis of Recurrent Events*. New York: Springer, 2007.
- [45] G. Corrao and G. Mancia. Generating evidence from computerized healthcare utilization databases. *Hypertension*, 65:490–498, 2015.
- [46] D. Cox. Regression models and life tables (with discussion). *Journal of the Royal Statistical Society, Series B*, 34(2):187–220, 1972.
- [47] D. Daley and D. Vere-Jones. *An Introduction to the Theory of Point Processes*. Springer-Verlag New York, 2nd edition, 2003.
- [48] R. M. Daniel, S. N. Cousens, B. L. De Stavola, *et al.* Methods for dealing with time-dependent confounding. *Statistics in medicine*, 32(9):1584–1618, 2013.
- [49] E. Dantan, P. Joly, J.-F. Dartigues, and H. Jacqmin-Gadda. Joint model with latent state for longitudinal and multistate data. *Biostatistics*, 12(4):723–736, 2011.
- [50] K. Dickstein, A. Cohen-Solal, G. Filippatos, *et al.* ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the european society of cardiology. developed in collaboration with the heart failure association of the ESC (HFA) and endorsed by the european society of intensive care medicine (ESICM). *European Journal of Heart Failure*, 10(10):933–989, 2008.

## Bibliography

- [51] N. A. G. dos Santos, R. S. Ferreira, and A. C. dos Santos. Overview of cisplatin-induced neurotoxicity and ototoxicity, and the protective agents. *Food and Chemical Toxicology*, 136:111079, 2020.
- [52] L. Duchateau, P. Janssen, I. Kezic, and C. Fortpiéd. Evolution of recurrent asthma event rate over time in frailty models. *Journal of the Royal Statistical Society: Series C (Applied Statistics)*, 52(3):355–363, 2003.
- [53] M. Elseviers, M. Andersen, A. B. Almarsdottir, *et al.* *Drug utilization research*. John Wiley & Sons, Nashville, TN, 2016.
- [54] T. Emura, M. Nakatochi, K. Murotani, and V. Rondeau. A joint frailty-copula model between tumour progression and death for meta-analysis. *Statistical methods in medical research*, 26(6):2649–2666, 2017.
- [55] T. Fawcett. An introduction to ROC analysis. *Pattern Recognit. Lett.*, 27(8):861–874, June 2006.
- [56] F. Ferraty and P. Vieu. *Nonparametric functional data analysis: theory and practice*. Springer Series in Statistics. Springer New York, 2006.
- [57] G. Fitzmaurice, M. Davidian, G. Verbeke, and G. Molenberghs. *Longitudinal data analysis*. Chapman & Hall, CRC, London, 2009.
- [58] C. A. Forbes, S. Deshpande, F. Sorio-Vilela, *et al.* A systematic literature review comparing methods for the measurement of patient persistence and adherence. *Current Medical Research and Opinion*, 34(9):1613–1625, 2018.
- [59] F. Gasperoni, F. Ieva, G. Barbati, *et al.* Multi-state modelling of heart failure care path: A population-based investigation from italy. *PLoS One*, 12(6):e0179176, 2017.
- [60] F. Gasperoni, F. Ieva, A. Paganoni, *et al.* Non-parametric frailty cox models for hierarchical time-to-event data. *Biostatistics*, 12 2018.
- [61] E. Gayat, M. Arrigo, S. Littnerova, *et al.* Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensity-score matched study. *European Journal of Heart Failure*, 20(2):345–354, 2018.
- [62] J. E. Gellar, E. Colantuoni, D. M. Needham, and C. M. Crainiceanu. Cox regression models with functional covariates for survival data. *Statistical Modelling*, 15(3):256–278, 2015.
- [63] A. Giardini, M. T. Martin, C. Cahir, *et al.* Toward appropriate criteria in medication adherence assessment in older persons: Position paper. *Aging Clinical and Experimental Research*, 28(3):371–381, 2016.
- [64] J. R. González, E. Fernandez, V. Moreno, *et al.* Sex differences in hospital readmission among colorectal cancer patients. *Journal of epidemiology and community health*, 59(6):506–511, 2005.
- [65] L. A. Gould, M. E. Boye, M. J. Crowther, *et al.* Joint modeling of survival and longitudinal non-survival data: current methods and issues. Report of the DIA Bayesian joint modeling working group. *Statistics in Medicine*, 34(14):2181–2195, 2015.
- [66] E. Graf, C. Schmoor, W. Sauerbrei, and M. Schumacher. Assessment and comparison of prognostic classification schemes for survival data. *Statistics in Medicine*, 18(17-18):2529–2545, 1999.
- [67] S. Greenland, J. Pearl, and J. M. Robins. Causal diagrams for epidemiologic research. *Epidemiology*, 10(1):37–48, 1999.
- [68] R. W. Gregg, J. M. Molepo, V. J. Monpetit, *et al.* Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. *Journal of Clinical Oncology*, 10(5):795–803, 1992.

- [69] T. Grimmsmann and W. Himmel. Discrepancies between prescribed and defined daily doses: a matter of patients or drug classes? *European Journal of Clinical Pharmacology*, 67(8):847–854, 2011.
- [70] S. K. Gupta. Intention-to-treat concept: A review. *Perspectives in clinical research*, 2(3):109–112, 2011.
- [71] H. Hao, L. Chen, D. Huang, *et al.* Meta-analysis of alkaline phosphatase and prognosis for osteosarcoma. *European Journal of Cancer Care*, 26(5):e12536, 2017.
- [72] C. Happ and S. Greven. Multivariate Functional Principal Component Analysis for Data Observed on Different (Dimensional) Domains. *Journal of the American Statistical Association*, 113(522):649–659, 2018.
- [73] X. He and P. Ng. Cobs: Qualitatively constrained smoothing via linear programming. *Computational Statistics*, 14(3):315–338, 1999.
- [74] P. J. Heagerty and Y. Zheng. Survival model predictive accuracy and ROC curves. *Biometrics*, 61(1):92–105, 2005.
- [75] P. A. Heidenreich, B. Bozkurt, D. Aguilar, *et al.* 2022 AHA/ACC/HFSA guideline for the management of heart failure: A report of the american college of Cardiology/American heart association joint committee on clinical practice guidelines. *Circulation*, 145(18):e895–e1032, 2022.
- [76] R. Henderson, P. Diggle, and A. Dobson. Joint modelling of longitudinal measurements and event time data. *Biostatistics*, 1(4):465–480, 2000.
- [77] M. Hernán and J. Robins. *Causal Inference: What If*. Boca Raton: Chapman & Hall/CRC, 2020.
- [78] M. A. Hernán, B. Brumback, and J. M. Robins. Marginal Structural Models to Estimate the Causal Effect of Zidovudine on the Survival of HIV-Positive Men. *Epidemiology*, 11(5):561–570, 2000.
- [79] M. A. Hernán, B. Brumback, and J. M. Robins. Marginal Structural Models to Estimate the Joint Causal Effect of Nonrandomized Treatments. *Journal of the American Statistical Association*, 96(454):440–448, 2001.
- [80] L. M. Hess, M. A. Raebel, D. A. Conner, and D. C. Malone. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. *Annals of Pharmacotherapy*, 40(7-8):1280–1288, 2006.
- [81] G. L. Hickey, P. Philipson, A. Jorgensen, and R. Kolamunnage-Dona. Joint modelling of time-to-event and multivariate longitudinal outcomes: recent developments and issues. *BMC Medical Research Methodology*, 16(117), 2016.
- [82] G. L. Hickey, P. Philipson, A. Jorgensen, and R. Kolamunnage-Dona. A comparison of joint models for longitudinal and competing risks data, with application to an epilepsy drug randomized controlled trial. *Journal of the Royal Statistical Society: Series A (Statistics in Society)*, 181(4):1105–1123, 2018.
- [83] G. L. Hickey, P. Philipson, A. Jorgensen, and R. Kolamunnage-Dona. Joint models of longitudinal and time-to-event data with more than one event time outcome: A review. *The International Journal of Biostatistics*, 14(1), 2018.
- [84] A. Hirakawa, K. Sudo, K. Yonemori, *et al.* A Comparative Study of Longitudinal Toxicities of Cytotoxic Drugs, Molecularly Targeted Agents, Immunomodulatory Drugs, and Cancer Vaccines. *Clinical Pharmacology & Therapeutics*, 106(4):803–809, 2019.
- [85] P. Hougaard. Frailty models for survival data. *Lifetime Data Analysis*, 1:255–273, 1995.

## Bibliography

- [86] W. M. Hryniuk and M. Goodyear. The calculation of received dose intensity. *Journal of Clinical Oncology*, 8(12):1935–1937, 1990.
- [87] S. A. Hunt, W. T. Abraham, M. H. Chin, *et al.* 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the american college of cardiology Foundation/American heart association task force on practice guidelines: developed in collaboration with the international society for heart and lung transplantation. *Circulation*, 119(14):e391–479, 2009.
- [88] J. Ibrahim, M. Chen, and D. Sinha. *Bayesian Survival Analysis*. Springer Series in Statistics. Springer, New York, NY, 2001.
- [89] F. Ieva and F. Gasperoni. Discussion of the paper "statistical challenges of administrative and transaction data" by david j. han. *Journal of the Royal Statistical Society - Series A*, 181(3):591–592, 2018.
- [90] F. Ieva, C. Jackson, and L. Sharples. Multi-state modelling of repeated hospitalisation and death in patients with heart failure: the use of large administrative databases in clinical epidemiology. *Statistical Methods in Medical Research*, 26(3):1350–1372, 2017.
- [91] F. Ieva and A. M. Paganoni. Risk prediction for myocardial infarction via generalized functional regression models. *Statistical Methods in Medical Research*, 25(4):1648–1660, 2016.
- [92] F. Ieva, A. M. Paganoni, D. Pigoli, and V. Vitelli. Multivariate functional clustering for the morphological analysis of electrocardiograph curves. *Journal of the Royal Statistical Society: Series C (Applied Statistics)*, 62(3):401–418, 2013.
- [93] A. Iorio, F. Rea, G. Barbati, *et al.* HF progression among outpatients with HF in a community setting. *International Journal of Cardiology*, 277:140–146, 2019.
- [94] A. Iorio, M. Senni, G. Barbati, *et al.* Prevalence and prognostic impact of non-cardiac co-morbidities in heart failure outpatients with preserved and reduced ejection fraction: a community-based study. *European Journal of Heart Failure*, 20(9):1257–1266, 2018.
- [95] A. Jahn-Eimermacher. Comparison of the Andersen–Gill model with poisson and negative binomial regression on recurrent event data. *Computational Statistics & Data Analysis*, 52(11):4989–4997, 2008.
- [96] B. Juang and L. Rabiner. Hidden Markov models for speech recognition. *Technometrics*, 33:251–272, 1991.
- [97] J. Kalbfleisch and R. Prentice. *The Statistical Analysis of Failure Time Data, 2nd Edition*. John Wiley & Sons, 360, 2011.
- [98] A. Kalogeropoulos, A. Samman-Tahhan, J. Hedley, *et al.* Progression to Stage D Heart Failure Among Outpatients With Stage C Heart Failure and Reduced Ejection Fraction. *JACC Heart Failure*, 5(7):528–537, 2017.
- [99] E. Kaplan and P. Meier. Nonparametric estimation from incomplete observations. *Journal of American Statistical Association*, 53:457–481, 1958.
- [100] M. E. Karim, P. Gustafson, J. Petkau, *et al.* Marginal Structural Cox Models for Estimating the Association Between  $\beta$ -Interferon Exposure and Disease Progression in a Multiple Sclerosis Cohort. *American Journal of Epidemiology*, 180(2):160–171, 2014.
- [101] M. E. Karim, J. Petkau, P. Gustafson, *et al.* On the application of statistical learning approaches to construct inverse probability weights in marginal structural cox models: Hedging against weight-model misspecification. *Communications in Statistics - Simulation and Computation*, 46(10):7668–7697, 2017.

- [102] S. Karve, M. A. Cleves, M. Helm, *et al.* Prospective validation of eight different adherence measures for use with administrative claims data among patients with schizophrenia. *Value in Health*, 12(6):989–995, 2009.
- [103] P. J. Kelly and L. L.-Y. Lim. Survival analysis for recurrent event data: an application to childhood infectious diseases. *Statistics in Medicine*, 19(1):13–33, 2000.
- [104] B. Kennedy. Repeated hospitalizations and self-rated health among the elderly: A multivariate failure time analysis. *American Journal of Epidemiology*, 153:232–241, 02 2001.
- [105] R. H. Keogh, S. R. Seaman, J. M. Gran, and S. Vansteelandt. Simulating longitudinal data from marginal structural models using the additive hazard model. *Biometrical Journal*, 63(7):1526–1541, 2021.
- [106] D. G. Kleinbaum and M. Klein. *Survival Analysis: A Self-Learning Text*. Statistics for Biology and Health. Springer New York, 2013.
- [107] M. Komajda, S. D. Anker, M. R. Cowie, *et al.* Physicians’ adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey. *European Journal of Heart Failure*, 18(5):514–522, May 2016.
- [108] M. Komajda, M. R. Cowie, L. Tavazzi, Filippatos, and QUALIFY Investigators. *et al.* Physicians’ guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. *European Journal of Heart Failure*, 19(11):1414–1423, 2017.
- [109] D. Kong, J. G. Ibrahim, E. Lee, and H. Zhu. Flcrm: Functional linear cox regression model. *Biometrics*, 74(1):109–117, 2018.
- [110] C. Lancia, J. Anninga, M. R. Sydes, *et al.* A novel method to address the association between received dose intensity and survival outcome: benefits of approaching treatment intensification at a more individualised level in a trial of the European Osteosarcoma Intergroup. *Cancer chemotherapy and pharmacology*, 83(5):951–962, 2019.
- [111] C. Lancia, J. Anninga, M. R. Sydes, *et al.* Method to measure the mismatch between target and achieved received dose intensity of chemotherapy in cancer trials: a retrospective analysis of the MRC BO06 trial in osteosarcoma. *BMJ open*, 9(5), 2019.
- [112] C. Lancia, C. Spitoni, J. Anninga, *et al.* Marginal structural models with dose-delay joint-exposure for assessing variations to chemotherapy intensity. *Statistical Methods in Medical Research*, 28(9):2787–2801, 2019.
- [113] G. Last and A. Brandt. *Marked Point Processes on the Real Line: The Dynamical Approach*. Springer-Verlag New York, 1995.
- [114] J. G. Le-Rademacher, S. Hillman, E. Storricks, *et al.* Adverse event burden score—a versatile summary measure for cancer clinical trials. *Cancers (Basel)*, 12(11):3251, 2020.
- [115] D. Lee, L. Donovan, P. Austin, *et al.* Comparison of coding of heart failure and comorbidities in administrative and clinical data for use in outcomes research. *Medical Care*, 43:182–188, 2005.
- [116] E. Lee, H. Zhu, D. Kong, *et al.* BFLCRM: A Bayesian functional linear Cox regression model for predicting time to conversion to Alzheimer’s disease. *The Annals of Applied Statistics*, 9(4):2153–2178, 2015.
- [117] S. Lee, D. Hershman, P. Martin, *et al.* Toxicity burden score: a novel approach to summarize multiple toxic effects. *Annals of Oncology*, 23(2):537–541, 2012.
- [118] A. Lehmann, P. Aslani, R. Ahmed, *et al.* Assessing medication adherence: options to consider. *International Journal of Clinical Pharmacy*, 36(1):55–69, 2014.



## Bibliography

- [119] I. Lewis, M. Nooij, J. Whelan, *et al.* Improvement in Histologic Response But Not Survival in Osteosarcoma Patients Treated With Intensified Chemotherapy: A Randomized Phase III Trial of the European Osteosarcoma Intergroup. *JNCI: Journal of the National Cancer Institute*, 99(2):112–128, 2007.
- [120] I. J. Lewis, S. Weeden, D. Machin, *et al.* Received dose and dose-intensity of chemotherapy and outcome in nonmetastatic extremity osteosarcoma. *Journal of Clinical Oncology*, 18(24):4028–4037, 2000.
- [121] K. Li and S. Luo. Dynamic prediction of Alzheimer’s disease progression using features of multiple longitudinal outcomes and time-to-event data. *Statistics in Medicine*, 38(24):4804–4818, 2019.
- [122] L. Li, T. Greene, and B. Hu. A simple method to estimate the time-dependent receiver operating characteristic curve and the area under the curve with right censored data. *Statistical Methods in Medical Research*, 27(8):2264–2278, 2018.
- [123] L. Li and C. Wu. *tdROC: Nonparametric Estimation of Time-Dependent ROC Curve from Right Censored Survival Data*, 2016. R package version 1.0, <https://CRAN.R-project.org/package=tdROC>
- [124] Z. Li, V. M. Chinchilli, and M. Wang. A Bayesian joint model of recurrent events and a terminal event. *Biometrical Journal*, 61(1):187–202, 2019.
- [125] Z. Li, V. M. Chinchilli, and M. Wang. A time-varying Bayesian joint hierarchical copula model for analysing recurrent events and a terminal event: an application to the Cardiovascular Health Study. *Journal of the Royal Statistical Society: Series C (Applied Statistics)*, 69(1):151–166, 2020.
- [126] D. Y. Lin. On fitting Cox’s proportional hazards models to survey data. *Biometrika*, 87:37–47, 2000.
- [127] B. Liu, Y. Huang, Y. Sun, *et al.* Prognostic value of inflammation-based scores in patients with osteosarcoma. *Scientific Reports*, 6(1), 2016.
- [128] X. Liu and M. C. K. Yang. Identifying temporally differentially expressed genes through functional principal components analysis. *Biostatistics*, 10(4):667–679, 2009.
- [129] D. Lloyd-Jones, R. Adams, T. Brown, *et al.* Executive summary: heart disease and stroke statistics—2010 update: a report from the American Heart Association. *Circulation*, 121:948–954, 2010.
- [130] A. P. Maggioni, S. D. Anker, U. Dahlström, *et al.* Are hospitalized or ambulatory patients with heart failure treated in accordance with european society of cardiology guidelines? evidence from 12,440 patients of the ESC heart failure Long-Term registry. *European Journal of Heart Failure*, 15(10):1173–1184, 2013.
- [131] A. P. Maggioni and F. Spandonaro. Lo scompenso cardiaco acuto in italia. *Giornale italiano di cardiologia (Rome)*, 15(2 Suppl 2):3S–4S, 2014.
- [132] L. Mancini and A. M. Paganoni. Marked point process models for the admissions of heart failure patients. *Statistical Analysis and Data Mining: The ASA Data Science Journal*, 12(2):125–135, 2019.
- [133] B. C. Martin, E. K. Wiley-Exley, S. Richards, *et al.* Contrasting measures of adherence with simple drug use, medication switching, and therapeutic duplication. *Annals of Pharmacotherapy*, 43(1):36–44, 2009.
- [134] A. Martino, A. Ghiglietti, F. Ieva, and A. M. Paganoni. A k-means procedure based on a Mahalanobis type distance for clustering multivariate functional data. *Statistical Methods & Applications*, 28(2):301–322, 2019.

- [135] J. A. Martín-Fernández, J. Palarea-Albaladejo, and R. A. Olea. Dealing with Zeros. In V. Pawlowsky-Glahn and A. Buccianti, editors, *Compositional Data Analysis*, chapter 4, pages 43–58. John Wiley & Sons, Ltd, 2011.
- [136] C. Mazzali, A. M. Paganoni, F. Ieva, *et al.* Methodological issues on the use of administrative data in healthcare research: The case of heart failure hospitalizations in Lombardy region, 2000 to 2012. *BMC Health Services Research*, 16(234), 2016.
- [137] P. McCullagh and J. Nelder. *Generalized Linear Models. Second edn.* Monographs on Statistics and Applied Probability. Chapman and Hall, 1989.
- [138] J. McMurray, A. Cohen-Solal, R. Dietz, *et al.* Practical recommendations for the use of ace inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: Putting guidelines into practice. *European Journal of Heart Failure*, 7(5):710–721, 2005.
- [139] J. J. McMurray, S. Adamopoulos, S. D. Anker, *et al.* ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. *European Heart Journal*, 14:803–869, 2012.
- [140] A. McTiernan, R. C. Jinks, M. R. Sydes, *et al.* Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup. *European Journal of Cancer*, 48(5):703–712, 2012.
- [141] MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). *The Lancet*, 353:2001–2007, 1999.
- [142] P. A. Meyer. A decomposition theorem for supermartingales. *Illinois J. Math.*, 6:193–205, 1962.
- [143] Ministero della Salute della Repubblica Italiana. *Scompenso Cardiaco*, 2022. [https://www.salute.gov.it/portale/salute/p1\\_5.jsp?area=Malattie\\_cardiovascolari&id=43&lingua=italiano](https://www.salute.gov.it/portale/salute/p1_5.jsp?area=Malattie_cardiovascolari&id=43&lingua=italiano)
- [144] H. Müller. Functional modelling and classification of longitudinal data. *Scandinavian Journal of Statistics*, 32:223–240, 2005.
- [145] W. Nelson. Hazard plotting for incomplete failure data. *Journal of Quality Technology.*, 1(1):27–52, 1969.
- [146] W. Nelson. Theory and applications of hazard plotting for censored failure data. *Technometrics*, 14(4):945–966, 1972.
- [147] L. Osterberg and T. Blaschke. Adherence to medication. *N. Engl. J. Med.*, 353(5):487–497, Aug. 2005.
- [148] W. Ouwerkerk, A. A. Voors, S. D. Anker, *et al.* Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective european study. *European Heart Journal*, 38(24):1883–1890, 2017.
- [149] A. Ozga, M. Kieser, and G. Rauch. A systematic comparison of recurrent event models for application to composite endpoints. *BMC Medical Research Methodology*, 18(2), 2018.
- [150] P. Pazos-López, J. Peteiro-Vázquez, A. Carcía-Campos, *et al.* The causes, consequences, and treatment of left or right heart failure. *Vascular Health Risk Management*, 7:237–254, 2011.
- [151] M. J. Pencina and R. B. D’Agostino. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. *Statistics in Medicine*, 23(13):2109–2123, 2004.

## Bibliography

- [152] M. J. Pencina, R. B. D'Agostino, Sr, R. B. D'Agostino, Jr, and R. S. Vasan. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. *Statistics in Medicine*, 27(2):157–72; discussion 207–12, Jan. 2008.
- [153] A. Peters and T. Hothorn. *ipred: Improved Predictors*, 2019. R package version 0.9-9, <https://CRAN.R-project.org/package=ipred>
- [154] P. Ponikowski, A. A. Voors, S. D. Anker, *et al.* 2016 esc guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the european society of cardiology (esc). developed with the special contribution of the heart failure association (hfa) of the esc. *European Heart Journal*, 37(27):2129–2200, 2016.
- [155] G. Prada-Ramallal, B. Takkouche, and A. Figueiras. Bias in pharmacoepidemiologic studies using secondary health care databases: a scoping review. *BMC Medical Research Methodology*, 19(1):53, 2019.
- [156] R. L. Prentice, B. J. Williams, and A. V. Peterson. On the regression analysis of multivariate failure time data. *Biometrika*, 68(2):373–379, 1981.
- [157] C. Proust-Lima, J. Dartigues, and H. Jacqmin-Gadda. Joint modeling of repeated multivariate cognitive measures and competing risks of dementia and death: a latent process and latent class approach. *Statistics in Medicine*, 35(3):382–398, 2016.
- [158] X. Qin, J. Hung, M. Knuiman, *et al.* Evidence-based pharmacotherapies used in the postdischarge phase are associated with improved one-year survival in senior patients hospitalized with heart failure. *Cardiovascular Therapeutics*, 36(6):e12464, Dec. 2018.
- [159] S. Qu, J. L. Wang, and X. Wang. Optimal estimation for the functional Cox model. *Annals of Statistics*, 44(4):1708–1738, 2016.
- [160] H. Quan, V. Sundararajan, P. Halfon, *et al.* Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. *Medical Care*, 43(11):1130–1139, 2005.
- [161] R Core Team. *R: A Language and Environment for Statistical Computing*. R Foundation for Statistical Computing, Vienna, Austria, 2018. <https://www.R-project.org/>
- [162] J. Ramsay and B. W. Silverman. *Functional Data Analysis*. Springer Series in Statistics. Springer, New York, NY, 2005.
- [163] J. O. Ramsay and B. W. Silverman. *Applied Functional Data Analysis: Methods and Case Studies*. Springer Series in Statistics. Springer New York, 2002.
- [164] Regione Lombardia. *HFDData project: Utilization of Regional Health Source Databases for Evaluating Epidemiology, short- and medium-term outcome and process indicators in patients hospitalized for heart failure*. Progetto di Ricerca Finalizzata di Regione Lombardia - HFDData-RF-2009-1483329, 2012.
- [165] H. Ren, L. Sun, H. Li, and Z. Ye. Prognostic Significance of Serum Alkaline Phosphatase Level in Osteosarcoma: A Meta-Analysis of Published Data. *BioMed Research International*, 2015(Article ID 160835), 2015.
- [166] J. Ritter and S. S. Bielack. Osteosarcoma. *Annals of Oncology*, 21(suppl 7):vii320–vii325, 2010.
- [167] D. Rizopoulos. *Joint Models for Longitudinal and Time-to-Event Data: With Applications in R*. Chapman and Hall/CRC, 2012.
- [168] D. Rizopoulos. The R Package JMbayes for fitting joint models for longitudinal and time-to-event data using MCMC. *Journal of Statistical Software*, 72(7), 2016.

- [169] J. Robins. A new approach to causal inference in mortality studies with a sustained exposure period—application to control of the healthy worker survivor effect. *Mathematical Modelling*, 7(9):1393–1512, 1986.
- [170] J. M. Robins, D. Blevins, G. Ritter, and M. Wulfsohn. G-estimation of the effect of prophylaxis therapy for *Pneumocystis carinii* pneumonia on the survival of AIDS patients. *Epidemiology*, 3(4):319–336, 1992.
- [171] J. M. Robins, M. A. Hernán, and B. Brumback. Marginal structural models and causal inference in epidemiology. *Epidemiology*, 11(5):550–560, 2000.
- [172] A. Rogatko, J. S. Babb, H. Wang, *et al.* Patient Characteristics Compete with Dose as Predictors of Acute Treatment Toxicity in Early Phase Clinical Trials. *Clinical Cancer Research*, 10(14):4645–4651, 2004.
- [173] J. K. Rogers, A. Yaroshinsky, S. J. Pocock, *et al.* Analysis of recurrent events with an associated informative dropout time: Application of the joint frailty model. *Statistics in Medicine*, 35(13):2195–2205, 2016.
- [174] V. Rondeau. Statistical models for recurrent events and death: Application to cancer events. *Mathematical and Computer Modelling*, 52(7):949–955, 2010.
- [175] V. Rondeau, D. Commenges, and P. Joly. Maximum Penalized Likelihood Estimation in a Gamma-Frailty Model. *Lifetime Data Analysis*, 9:139–153, 2003.
- [176] V. Rondeau, L. Filleul, and P. Joly. Nested frailty models using maximum penalized likelihood estimation. *Statistics in Medicine*, 25(23):4036–4052, 2006.
- [177] V. Rondeau, S. Mathoulin-Pelissier, H. Jacqmin-Gadda, *et al.* Joint frailty models for recurring events and death using maximum penalized likelihood estimation: application on cancer events. *Biostatistics*, 8(4):708–721, 2007.
- [178] G. Rosen and A. Nirenberg. Neoadjuvant chemotherapy for osteogenic sarcoma: a five year follow-up (t-10) and preliminary report of new studies (t-12). *Progress in clinical and biological research*, 201:39–51, 1985.
- [179] T. M. Ruppap, P. S. Cooper, D. R. Mehr, *et al.* Medication adherence interventions improve heart failure mortality and readmission rates: Systematic review and meta-analysis of controlled trials. *Journal of the American Heart Association*, 5(6), 2016.
- [180] J. Saczynski, S. Andrade, L. Harrold, *et al.* A systematic review of validated methods for identifying heart failure using administrative data. *Pharmacoepidemiology & Drug Safety*, 21:129–140, 2012.
- [181] M. Schemper and R. Henderson. Predictive accuracy and explained variation in cox regression. *Biometrics*, 56(1):249–255, 2000.
- [182] M. Schemper and T. L. Smith. A note on quantifying follow-up in studies of failure time. *Controlled Clinical Trials*, 17(4):343–346, 1996.
- [183] G. Schwarz. Estimating the Dimension of a Model. *The Annals of Statistics*, 6(2):461–464, 1978.
- [184] S. Sivendran, A. Latif, R. B. McBride, *et al.* Adverse Event Reporting in Cancer Clinical Trial Publications. *Journal of Clinical Oncology*, 32(2):83–89, 2014.
- [185] S. Smeland, S. S. Bielack, J. Whelan, *et al.* Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. *European Journal of Cancer*, 109:36–50, 2019.

## Bibliography

- [186] R. L. Souhami, A. W. Craft, J. W. Van der Eijken, *et al.* Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. *The Lancet*, 350(9082):911–917, 1997.
- [187] M. Spreafico, F. Gasperoni, G. Barbati, *et al.* Adherence to Disease-Modifying Therapy in Patients Hospitalized for HF: Findings from a Community-Based Study. *American Journal of Cardiovascular Drugs*, 20:179–190, 2020.
- [188] M. Spreafico and F. Ieva. Dynamic monitoring of the effects of adherence to medication on survival in heart failure patients: A joint modeling approach exploiting time-varying covariates. *Biometrical Journal*, 63(2):305–322, 2021.
- [189] M. Spreafico and F. Ieva. Functional modeling of recurrent events on time-to-event processes. *Biometrical Journal*, 63(5):948–967, 2021.
- [190] M. Spreafico, F. Ieva, F. Arlati, *et al.* Novel longitudinal Multiple Overall Toxicity (MOTox) score to quantify adverse events experienced by patients during chemotherapy treatment: a retrospective analysis of the MRC BO06 trial in osteosarcoma. *BMJ Open*, 11(12):e053456, 2021.
- [191] M. Spreafico, F. Ieva, and M. Fiocco. Longitudinal Latent Overall Toxicity (LOTox) profiles in osteosarcoma: a new taxonomy based on latent Markov models. *arXiv*, 2107.12863, 2021. <https://arxiv.org/abs/2107.12863>
- [192] M. Spreafico, F. Ieva, and M. Fiocco. Modelling time-varying covariates effect on survival via Functional Data Analysis: application to the MRC BO06 trial in osteosarcoma. *Statistical Methods & Applications*, 2022. <https://doi.org/10.1007/s10260-022-00647-0>
- [193] J. F. Steiner. Measuring adherence with medications: time is of the essence. *Pharmacoepidemiology & Drug Safety*, 25(3):333–335, 2016.
- [194] B. L. Strom, editor. *Pharmacoepidemiology*. John Wiley & Sons, Ltd, Chichester, UK, 2003.
- [195] B. L. Strom and S. E. Kimmel, editors. *Textbook of Pharmacoepidemiology*. John Wiley & Sons, Chichester, England, 2006.
- [196] C. L. Su and F. C. Lin. Analysis of cyclic recurrent event data with multiple event types. *Japanese Journal of Statistics and Data Science*, 4(2):895–915, 2021.
- [197] L. Sun, L. Zhu, and J. Sun. Regression analysis of multivariate recurrent event data with time-varying covariate effects. *Journal of Multivariate Analysis*, 100(10):2214 – 2223, 2009.
- [198] G. Thanarajasingam, P. J. Atherton, P. J. Novotny, *et al.* Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254. *The Lancet Oncology*, 17(5):663–670, 2016.
- [199] G. Thanarajasingam, J. M. Hubbard, J. A. Sloan, and A. Grothey. The Imperative for a New Approach to Toxicity Analysis in Oncology Clinical Trials. *JNCI: Journal of the National Cancer Institute*, 107(10), 08 2015. djv216.
- [200] G. Thanarajasingam, J. P. Leonard, T. E. Witzig, *et al.* Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial. *The Lancet Haematology*, 7(6):e490–e497, 2020.
- [201] T. M. Therneau. *A Package for Survival Analysis in R*, 2020. R package version 3.1-11, <https://CRAN.R-project.org/package=survival>
- [202] T. M. Therneau and P. Grambsch. *Modeling Survival Data: Extending the Cox Model*. Springer, New York, 2000.

- [203] T. M. Therneau, P. M. Grambsch, and T. R. Fleming. Martingale-based residuals for survival models. *Biometrika*, 77(1):147–160, 03 1990.
- [204] A. Trotti, A. Colevas, A. Setser, *et al.* CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. *Seminars in Radiation Oncology*, 13(3):176–181, 2003.
- [205] A. Trotti, T. F. Pajak, C. K. Gwede, *et al.* TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group. *The Lancet Oncology*, 8(7):613–624, 2007.
- [206] A. A. Tsiatis and M. Davidian. Joint modelling of longitudinal and time-to-event data: an overview. *Statistica Sinica*, 14(3):809–834, 2004.
- [207] S. Ullah and C. F. Finch. Applications of functional data analysis: A systematic review. *BMC Medical Research Methodology*, 13(43), 2013.
- [208] U.S. Department of Health and Human Services. *Common Terminology Criteria for Adverse Events v3.0 (CTCAE)*, 2006. [https://www.eortc.be/services/doc/ctc/ctcae\\_v3.pdf](https://www.eortc.be/services/doc/ctc/ctcae_v3.pdf).
- [209] S. van Buuren and K. Groothuis-Oudshoorn. mice: Multivariate imputation by chained equations inr. *J. Stat. Softw.*, 45(3), 2011.
- [210] W. M. van der Wal and R. B. Geskus. ipw: An R package for inverse probability weighting. *Journal of Statistical Software*, 43(13):1–23, 2011.
- [211] A. Viterbi. Error bounds for convolutional codes and an asymptotically optimum decoding algorithm. *IEEE Transactions on Information Theory*, 13(2):260–269, 1967.
- [212] B. Vrijens, S. De Geest, D. A. Hughes, *et al.* A new taxonomy for describing and defining adherence to medications. *British Journal of Clinical Pharmacology*, 73(5):691–705, 2012.
- [213] L. J. Wei, D. Y. Lin, and L. Weissfeld. Regression Analysis of Multivariate Incomplete Failure Time Data by Modeling Marginal Distributions. *Journal of the American Statistical Association*, 84(408):1065–1073, 1989.
- [214] WHO Collaborating Centre for Drug Statistics Methodology. <https://www.whocc.no>
- [215] WHO, International League Against Epilepsy and International Bureau for Epilepsy. *Atlas: Epilepsy Care in the World 2005*. Geneva: World Health Organization, 2005.
- [216] L. Wiggins. *Panel analysis: latent probability models for attitude and behaviour processes*. Elsevier, Amsterdam, 1973.
- [217] T. Williamson and P. Ravani. Marginal structural models in clinical research: when and how to use them? *Nephrology Dialysis Transplantation*, 32(suppl 2):ii84–ii90, 2017.
- [218] M. A. Williamson, L. M. Snyder, and J. B. Wallach. *Wallach’s Interpretation of Diagnostic Tests: Pathways to Arriving at a Clinical Diagnosis. Tenth Edition*. Philadelphia: Wolters Kluwer Health, 2015.
- [219] World Health Organization. *Adherence to Long-Term Therapies: Evidence for Action*. WHO Library Cataloguing-in-Publication Data, 2003.
- [220] World Health Organization, WHO International Working Group for Drug Statistics Methodology, WHO Collaborating Centre for Drug Statistics Methodology, and WHO Collaborating Centre for Drug Utilization Research and Clinical Pharmacological Service. *Introduction to Drug Utilization Research*. WHO Library Cataloguing-in-Publication Data, 2003.

## Bibliography

- [221] WRITING COMMITTEE MEMBERS, C. W. Yancy, M. Jessup, *et al.* 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: An update of the 2013 ACCF/AHA guideline for the management of heart failure: A report of the american college of cardiology/american heart association task force on clinical practice guidelines and the heart failure society of america. *Circulation*, 134(13):e282–93, 2016.
- [222] C. W. Yancy, M. Jessup, B. Bozkurt, *et al.* 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the american college of cardiology Foundation/American heart association task force on practice guidelines. *Circulation*, 128(16):1810–1852, Oct. 2013.
- [223] F. Yao, H. Müller, and J. Wang. Functional Data Analysis for Sparse Longitudinal Data. *Journal of the American Statistical Association*, 100(470):577–590, 2005.
- [224] P. Ye, X. Zhao, L. Sun, and W. Xu. A semiparametric additive rates model for multivariate recurrent events with missing event categories. *Computational Statistics & Data Analysis*, 89:39 – 50, 2015.
- [225] B. S. Yoo, J. Oh, B. K. Hong, *et al.* SURvey of Guideline Adherence for Treatment of Systolic Heart Failure in Real World (SUGAR): a multi-center, retrospective, observational study. *PLoS One*, 9(1):e86596, Jan. 2014.
- [226] S. Zhang, Q. Chen, and Q. Wang. The use of and adherence to CTCAE v3.0 in cancer clinical trial publications. *Oncotarget*, 7(40):65577–65588, 2016.
- [227] L. Zhao and B. Zhang. Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes. *Scientific Reports*, 7:44735, 2017.
- [228] S. Zhou, A. Starkov, M. K. Froberg, *et al.* Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. *Cancer research*, 61(2):771–777, 2001.